The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2017 | An introduction to the HOVON-141 trial in patients with CLL
Arnon Kater, MD, PhD from the University of Amsterdam, Amsterdam, Netherlands talks to us about the new HOVON -141 trial, a collaboration between the HOVON group and the Nordic chronic lymphocytic leukemia (CLL) study group. This trial will be asking the important question of, is it better to stop treatment in patients earlier rather than later? Prof. Kater discusses the challenges associated with long term treatment in CLL and the concept of stopping treatment when patients reach minimal residual disease (MRD) status. This interview was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY.
